Search Result

Isoforms Recommended:	Akt2

Results for "

Akt2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (41) AMPK (1) Apoptosis (7) Autophagy (6) Bacterial (2) Bcl-2 Family (1) Caspase (2) FKBP (1) Influenza Virus (1) Organoid (4) Parasite (2) PKA (4) PKC (4) PROTAC Linkers (1) PROTACs (4) Ribosomal S6 Kinase (RSK) (4) ROCK (4) Ser/Thr Protease (1) SGK (2) Small Interfering RNA (siRNA) (3) VEGFR (1)
By Research Areas:	Cancer (43) Infection (5) Inflammation/Immunology (3) Metabolic Disease (2)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50862

Akt1/Akt2-IN-1	Akt	Cancer
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of *Akt1* (IC₅₀=3.5 nM) and *Akt2* (IC₅₀=42 nM), with potent and balanced activity .

HY-19982

AKT-IN-6	Akt	Cancer
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

HY-100018

BAY1125976 1 Publications Verification	Akt	Cancer
BAY1125976 is a selective allosteric *Akt1/Akt2* inhibitor; inhibits Akt1 and Akt2 activity with IC₅₀ values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

HY-RS00546

AKT2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
AKT2 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT2 Human Pre-designed siRNA Set A AKT2 Human Pre-designed siRNA Set A

HY-RS00547

Akt2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Akt2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt2 Mouse Pre-designed siRNA Set A Akt2 Mouse Pre-designed siRNA Set A

HY-RS00548

Akt2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Akt2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt2 Rat Pre-designed siRNA Set A Akt2 Rat Pre-designed siRNA Set A

HY-129119

Akt1/Akt2-IN-2	Akt Caspase	Cancer
Akt1/Akt2-IN-2 (compound 7) is an allosteric dual *Akt1* and *Akt2* inhibitor (IC₅₀=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells .

HY-143611

AKT-IN-8	Akt	Cancer
AKT-IN-8 is a potent *AKT* inhibitor with IC₅₀s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively .

HY-153640

AKT-IN-14	Akt	Cancer
AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research .

HY-153640A

AKT-IN-14 free base	Akt	Cancer
AKT-IN-14 (Example 2) free baseis a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 free basecan be used in cancer research .

HY-16666

3CAI 3 Publications Verification	Akt	Cancer
3CAI is a potent and specific *AKT1* and *AKT2* inhibitor.

HY-145281

MS98	PROTACs Akt	Cancer
MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with K_ds of 4 nM, 140 nM, and 8.1 nM, respectively .

HY-145282

MS170	PROTACs Akt	Cancer
MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively .

HY-15431

Capivasertib 55+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and *Akt3*, respectively.

HY-138767

AKT-IN-5	Akt	Cancer
AKT-IN-5 (Example 8) is a *Akt* inhibitor with IC₅₀ values of 450 nM and 400 nM for *Akt1* and *Akt2*, respectively .

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-15965A

Uprosertib hydrochloride GSK2141795 hydrochloride	Akt	Cancer
Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-102080

SAFit2 4 Publications Verification	FKBP	Cancer
SAFit2 is a highly potent, highly selective FK506-binding protein 51 (FKBP51) inhibitor with a K_i of 6 nM and also enhances *AKT2-AS160* binding .

HY-10425

A-443654 5+ Cited Publications	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against *Akt1, Akt2, or Akt3* within cells (K_i=160 pM) .

HY-19719

Miransertib 10+ Cited Publications ARQ-092	Akt Parasite	Infection Cancer
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania* ^[2].

HY-19719A

Miransertib hydrochloride 10+ Cited Publications ARQ-092 hydrochloride	Akt Parasite	Infection Cancer
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania* ^[2].

HY-15186A

Ipatasertib dihydrochloride 40+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for *Akt1, Akt2* and *Akt3*, respectively.

HY-15727

Afuresertib 10+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively ^[2].

HY-15727A

Afuresertib hydrochloride 10+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively ^[2].

HY-133120

INY-03-041	PROTACs Akt	Cancer
INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-12059

AT7867 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-12059A

AT7867 dihydrochloride 5 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of *Akt1/Akt2/Akt3* and p70S6K/PKA with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-10355

AKT inhibitor VIII 40+ Cited Publications Akti-1/2	Akt Apoptosis	Metabolic Disease Cancer
AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit *Akt1, Akt2, and Akt3* activity with IC₅₀s of 58 nM, 210 nM, and 2119 nM, respectively.

HY-N0004

Oridonin 15+ Cited Publications NSC-250682; Isodonol	Akt Bacterial	Infection Inflammation/Immunology Cancer
Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of *AKT, with IC₅₀s of 8.4 and 8.9 μM for AKT1 and AKT2*; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

HY-132302

Hu7691	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice .

HY-147937

AKT-IN-13	Akt	Cancer
AKT-IN-13 (compound 4b) is a potent *Akt* inhibitor with IC₅₀s of 1.6 nM, 2.4 nM and 0.3 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-13 can be used for researching anticancer .

HY-10358

MK-2206 dihydrochloride Maximum Cited Publications 338 Publications Verification MK-2206 (2HCl)	Organoid Akt Autophagy Apoptosis	Cancer
MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric *AKT* inhibitor with IC₅₀s of 5 nM, 12 nM, and 65 nM for *AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy* ^[2].

HY-132302A

Hu7691 free base	Akt PKA PKC ROCK Ribosomal S6 Kinase (RSK) SGK	Cancer
Hu7691 free base is an orally active, selective *Akt* inhibitor with IC₅₀s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice .

HY-N0004R

Oridonin (Standard)	Akt Bacterial	Infection Inflammation/Immunology Cancer
Oridonin (Standard) is the analytical standard of Oridonin. This product is intended for research and analytical applications. Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.

HY-151504

ALM301 1 Publications Verification	Akt	Cancer
ALM301 is an orally active highly specific *AKT* inhibitor with IC₅₀ values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth .

HY-10249

GSK-690693 30+ Cited Publications	Akt AMPK Autophagy	Cancer
GSK-690693 is an ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 2 nM, 13 nM, 9 nM for *Akt1, Akt2* and *Akt3, respectively. GSK-690693 is also an AMPK* inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation ^[2] .

HY-108232

MK-2206	Organoid Akt Autophagy Apoptosis	Cancer
MK-2206 is an orally active, highly potent and selective allosteric *Akt* inhibitor, with IC₅₀s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities ^[2].

HY-133120A

INY-03-041 trihydrochloride	PROTACs Akt	Cancer
INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 trihydrochloride inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively .

HY-B1080A

Tilorone 2 Publications Verification	Influenza Virus Akt	Infection Metabolic Disease Inflammation/Immunology Cancer
Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels ^[2] .

HY-13260

CCT128930 5 Publications Verification	Akt Autophagy Apoptosis	Cancer
CCT128930 is a ATP-competitive and selective inhibitor of *AKT* (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

HY-137458

Vevorisertib ARQ 751	Akt Ser/Thr Protease	Cancer
Vevorisertib (ARQ 751) is an orally active, potent and selective *pan-AKT* serine/threonine kinase inhibitor against *AKT1* (IC₅₀=0.55 nM), *AKT2* (IC₅₀=0.81 nM), and *AKT3* (IC₅₀=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations ^[2] .

HY-10357

MK-2206 free base	Organoid Akt Autophagy Apoptosis	Cancer
MK-2206 free base is an orally active, highly potent and selective allosteric *Akt* inhibitor, with IC₅₀s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206 free base. MK-2206 free base has anticancer activities ^[2].

HY-137458A

Vevorisertib trihydrochloride ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer .

HY-126257

AKT-IN-3	Akt Apoptosis	Cancer
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking *Akt* inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .

HY-130985

9-Decyn-1-ol	PROTAC Linkers	Cancer
9-Decyn-1-ol is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs. 9-Decyn-1-ol can be used to conjugate GDC-0068 with Lenalidomide to generate INY-03-041. INY-03-041 is a potent, highly selective and PROTAC-based pan-Akt degrader. INY-03-041 inhibits Akt1, Akt2 and Akt3 with IC₅₀s of 2.0 nM, 6.8 nM and 3.5 nM, respectively . 9-Decyn-1-ol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169431

*VEGFR-2/AKT-IN-2*	VEGFR Akt Caspase Bcl-2 Family Apoptosis	Cancer
VEGFR-2/AKT-IN-2 (Compound 5) is a *VEGFR-2/AKT* inhibitor (IC₅₀: 0.061 μM for VEGFRin HepG2 cell). VEGFR-2/AKT-IN-2 reduces total and phosphorylated *AKT* as well as up-regulates BAX and Caspase-3 and down-regulates *Bcl-2* in cells, thereby promoting Apoptosis. VEGFR-2/AKT-IN-2 causes cell cycle arrest in S phase. VEGFR-2/AKT-IN-2 inhibits the growth of human liver tumor cells .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

3,012 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,012 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Recombinant Proteins Recommended:

AKT Serine/Threonine Kinase 2 (AKT2)

Species:	Human (2) Mouse (1)
Tag:	His (2) Myc (1) GST (2)
Source:	Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74420

	AKT2 Protein, Human (sf9, His-GST) RAC-beta serine/threonine-protein kinase; PKB beta; Akt2	Human	Sf9 insect cells
	The AKT2 protein is a serine/threonine protein kinase in the AKT family that is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage. AKT2 Protein, Human (sf9, His-GST) is the recombinant human-derived AKT2 protein, expressed by Sf9 insect cells , with C-His, N-GST labeled tag. The total length of AKT2 Protein, Human (sf9, His-GST) is 481 a.a., with molecular weight of ~83.6 kDa.

HY-P702854

	AKT2 Protein, Mouse (His, Myc) Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta	Mouse	E. coli
	AKT2 Protein, Mouse (His, Myc) is the recombinant mouse-derived AKT2, expressed by E. coli , with N-10*His, C-Myc labeled tag. The total length of AKT2 Protein, Mouse (His, Myc) is 481 a.a.,

HY-P702632

	AKT2 Protein, Human (Active, sf9, GST) Akt2; v-Akt murine thymoma viral oncogene homolog 2; PKBB; PRKBB; PKBBETA; RAC-BETA; Akt2 kinase; rac protein kinase beta; Murine thymoma viral (v-Akt) homolog-2; EC 2.7.11.1; RAC-beta serine/threonine-protein kinase; RAC-PK-beta; Protein kinase Akt-2; Protein kinase B, beta; PKB beta	Human	Sf9 insect cells
	The AKT2 protein is a serine/threonine protein kinase in the AKT family that is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage. AKT2 Protein, Human (Active, sf9, GST) is the recombinant human-derived AKT2, expressed by Sf9 insect cells , with GST labeled tag. The total length of AKT2 Protein, Human (Active, sf9, GST) is 480 a.a.,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80535

	AKT1/AKT2/AKT3 Antibody (YA635) Akt1,Akt2,Akt3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to AKT. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.